Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model Steve ChoyEmilie HéninMats O. Karlsson Original Paper 24 November 2012 Pages: 1 - 10
Fractal structure of the liver: effect on drug elimination Michael Weiss Original Paper 05 December 2012 Pages: 11 - 14
Variability and singularity arising from poor compliance in a pharmacokinetic model I: the multi-IV case Pierre-Emmanuel Lévy VéhelJacques Lévy Véhel Original Paper 30 December 2012 Pages: 15 - 39
Compliance spectrum as a drug fingerprint of drug intake and drug disposition Olivier BarrièreJun LiFahima Nekka Original Paper 19 December 2012 Pages: 41 - 52
Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator Xin ZhangKaren SchneckVikram Sinha Original Paper 22 December 2012 Pages: 53 - 65
Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model Karen B. SchneckXin ZhangVikram P. Sinha Original Paper 22 December 2012 Pages: 67 - 80
Latent variable indirect response modeling of categorical endpoints representing change from baseline Chuanpu HuZhenhua XuHonghui Zhou Original Paper 30 December 2012 Pages: 81 - 91
The design and analysis of parallel experiments to produce structurally identifiable models S. Y. Amy CheungJames W. T. YatesLeon Aarons Original Paper 09 January 2013 Pages: 93 - 100
The effects of active metabolites on parameter estimation in linear mixed effect models of concentration–QT analyses Peter L. Bonate Original Paper 04 January 2013 Pages: 101 - 115
Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat Carl-Christer JohanssonPeter GennemarkRasmus Jansson-Löfmark Original Paper 10 January 2013 Pages: 117 - 128